Literature DB >> 25900119

Rapid Antidepressant Action and Restoration of Excitatory Synaptic Strength After Chronic Stress by Negative Modulators of Alpha5-Containing GABAA Receptors.

Jonathan Fischell1,2, Adam M Van Dyke1,3,4, Mark D Kvarta1,3,4,5, Tara A LeGates1, Scott M Thompson1,6.   

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are the primary pharmacological treatment for depression, but SSRIs are effective in only half of the patients and typically take several weeks to relieve symptoms. The NMDA receptor antagonist ketamine exerts a rapid antidepressant action, but has troubling side effects. We hypothesized that negative allosteric modulators of GABAA receptors would exert similar effects on brain activity as ketamine, but would not exert as many side effects if targeted only to GABAA receptors containing α5 subunits, which are enriched in the hippocampus and prefrontal cortex. Here, we show that the α5-selective negative modulator L-655,708 reversed the alterations in hedonic behavior in the sucrose preference and social interaction tests produced by two different chronic stress paradigms in rats within 24 h of systemic administration. Similar effects were observed with another α5-selective negative modulator, MRK-016. L-655,708 had no effect on hedonic or open-field behavior in unstressed animals. Within 24 h, L-655,708 injection also restored the strength of pathologically weakened excitatory synaptic transmission at the stress-sensitive temporoammonic-CA1 synapse, measured electrophysiologically, and increased levels of the GluA1 subunit of the AMPA receptor, measured with western blotting. We suggest that the ability of L-655,708 to restore excitatory synaptic strength rapidly may underlie its ability to restore stress-induced behavioral alterations rapidly, supporting evidence that dysfunction of multiple excitatory synapses in cortico-mesolimbic reward pathways contributes, in part, to the genesis of depression. Negative allosteric modulators of α5 subunit-containing GABAA receptors represent a promising novel class of fast-acting and clinically viable antidepressant compounds.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25900119      PMCID: PMC4569955          DOI: 10.1038/npp.2015.112

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  63 in total

1.  Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex.

Authors:  Eunice Y Yuen; Jing Wei; Wenhua Liu; Ping Zhong; Xiangning Li; Zhen Yan
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

2.  Differential effects produced by ketamine on oscillatory activity recorded in the rat hippocampus, dorsal striatum and nucleus accumbens.

Authors:  Mark J Hunt; Monika Falinska; Szymon Łeski; Daniel K Wójcik; Stefan Kasicki
Journal:  J Psychopharmacol       Date:  2010-04-22       Impact factor: 4.153

3.  mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Authors:  Nanxin Li; Boyoung Lee; Rong-Jian Liu; Mounira Banasr; Jason M Dwyer; Masaaki Iwata; Xiao-Yuan Li; George Aghajanian; Ronald S Duman
Journal:  Science       Date:  2010-08-20       Impact factor: 47.728

Review 4.  The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease.

Authors:  N B Farber; J W Newcomer; J W Olney
Journal:  Prog Brain Res       Date:  1998       Impact factor: 2.453

Review 5.  Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents.

Authors:  Ronald S Duman; Bhavya Voleti
Journal:  Trends Neurosci       Date:  2012-01       Impact factor: 13.837

6.  Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia.

Authors:  Kara Kittelberger; Elizabeth E Hur; Saba Sazegar; Vidya Keshavan; Bernat Kocsis
Journal:  Brain Struct Funct       Date:  2011-10-07       Impact factor: 3.270

7.  Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.

Authors:  Brian R Cornwell; Giacomo Salvadore; Maura Furey; Craig A Marquardt; Nancy E Brutsche; Christian Grillon; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2012-04-21       Impact factor: 13.382

Review 8.  Synaptic mechanisms underlying rapid antidepressant action of ketamine.

Authors:  Ege T Kavalali; Lisa M Monteggia
Journal:  Am J Psychiatry       Date:  2012-11       Impact factor: 18.112

9.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

10.  Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens.

Authors:  Byung Kook Lim; Kee Wui Huang; Brad A Grueter; Patrick E Rothwell; Robert C Malenka
Journal:  Nature       Date:  2012-07-11       Impact factor: 49.962

View more
  40 in total

1.  Corticosterone mediates the synaptic and behavioral effects of chronic stress at rat hippocampal temporoammonic synapses.

Authors:  Mark D Kvarta; Keighly E Bradbrook; Hannah M Dantrassy; Aileen M Bailey; Scott M Thompson
Journal:  J Neurophysiol       Date:  2015-07-15       Impact factor: 2.714

Review 2.  Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.

Authors:  Ronald S Duman; Gerard Sanacora; John H Krystal
Journal:  Neuron       Date:  2019-04-03       Impact factor: 17.173

Review 3.  Ketamine: Leading us into the future for development of antidepressants.

Authors:  Flavia R Carreno; Daniel J Lodge; Alan Frazer
Journal:  Behav Brain Res       Date:  2020-02-02       Impact factor: 3.332

Review 4.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

Review 5.  Mechanisms of ketamine action as an antidepressant.

Authors:  P Zanos; T D Gould
Journal:  Mol Psychiatry       Date:  2018-03-13       Impact factor: 15.992

Review 6.  Somatostatin-Positive Gamma-Aminobutyric Acid Interneuron Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives.

Authors:  Corey Fee; Mounira Banasr; Etienne Sibille
Journal:  Biol Psychiatry       Date:  2017-06-08       Impact factor: 13.382

Review 7.  Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders.

Authors:  Thomas Prévot; Etienne Sibille
Journal:  Mol Psychiatry       Date:  2020-04-28       Impact factor: 15.992

8.  Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy.

Authors:  Allie J Widman; Lori L McMahon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-12       Impact factor: 11.205

Review 9.  An Emerging Circuit Pharmacology of GABAA Receptors.

Authors:  Elif Engin; Rebecca S Benham; Uwe Rudolph
Journal:  Trends Pharmacol Sci       Date:  2018-06-11       Impact factor: 14.819

10.  Contribution of GABAA receptor subunits to attention and social behavior.

Authors:  Tracie A Paine; Sara Chang; Rachel Poyle
Journal:  Behav Brain Res       Date:  2019-09-24       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.